Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 914 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 


 
REVIEW ARTICLE Table of Contents   
Year : 2010  |  Volume : 21  |  Issue : 6  |  Page : 1021-1029
Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant


1 Division of Acute Medicine, The James Cook University Hospital, Marton Road, Middlesbrough, United Kingdom
2 Nephrology Department, Royal Liverpool and Broadgreen University Hospitals, Liverpool, United Kingdom

Correspondence Address:
Mohamed H Ahmed
Division of Acute Medicine, The James Cook University Hospital, Marton Road, Middlesbrough ,TS4 3BW
United Kingdom
Login to access the Email id


PMID: 21060168

Rights and Permissions

Individuals with chronic renal disease (CKD) are prone to have accelerated process of atherosclerosis. Importantly, cardiovascular disease is the main cause of morbidity and mortality in kidney transplant recipients. Recent studies suggest a potential benefit of the lipid lowering medica­tions in preventing cardiovascular events in the CKD and the transplant populations. In particular, statin was shown to be effective in reducing low density lipoprotein (LDL)-cholesterol. However, refractory dyslipidemia and difficulty in lowering LDL to target were reported with the CKD and the kidney transplant patients. The second United Kingdom Heart and Renal protection study (UK­HARP-II) showed that the addition of ezetimibe to simvastatin was safe and effective in treating dyslipidemia in CKD. Furthermore, the combination of ezetimibe and statin was also effective and safe in treating dyslipidemia in kidney transplant recipients. The Study of Heart and Renal Pro­tection (SHARP) trial will evaluate the effects of lowering LDL-C with ezetimibe 10 mg and simvastatin 20 mg daily versus placebo in 9,000 patients with chronic kidney disease. The current evidence suggests that the addition of ezetimibe to satin is effective and safe in treating dyslipidemia in the CKD and the kidney transplant patients. Future clinical trials are needed to determine whether ezetimibe will reduce cardiovascular risk in the CKD patients.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4305    
    Printed167    
    Emailed0    
    PDF Downloaded1266    
    Comments [Add]    
    Cited by others 1    

Recommend this journal